156 related articles for article (PubMed ID: 37942588)
21. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
Alkabbani W; Shah BR; Zongo A; Eurich DT; Alsabbagh MW; Gamble JM
Diabetes Obes Metab; 2023 Dec; 25(12):3490-3500. PubMed ID: 37563767
[TBL] [Abstract][Full Text] [Related]
22. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
23. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Neuen BL; Oshima M; Perkovic V; Agarwal R; Arnott C; Bakris G; Cannon CP; Charytan DM; Edwards R; Górriz JL; Jardine MJ; Levin A; Neal B; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Mahaffey KW; Heerspink HJL
Eur Heart J; 2021 Dec; 42(48):4891-4901. PubMed ID: 34423370
[TBL] [Abstract][Full Text] [Related]
24. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Cha SA; Park YM; Yun JS; Lim TS; Song KH; Yoo KD; Ahn YB; Ko SH
Lipids Health Dis; 2017 Apr; 16(1):58. PubMed ID: 28403877
[TBL] [Abstract][Full Text] [Related]
25. Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis.
Charlwood C; Chudasama J; Darling AL; Logan Ellis H; Whyte MB
Diabetes Res Clin Pract; 2023 Feb; 196():110239. PubMed ID: 36610543
[TBL] [Abstract][Full Text] [Related]
26. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
[TBL] [Abstract][Full Text] [Related]
27. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
29. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
31. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
33. Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history.
Kim JH; Lyu YS; Kim B; Kim MK; Kim SY; Baek KH; Song KH; Han K; Kwon HS
Diabetes Obes Metab; 2024 Jul; 26(7):2567-2577. PubMed ID: 38644477
[TBL] [Abstract][Full Text] [Related]
34. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
35. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
36. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
[TBL] [Abstract][Full Text] [Related]
37. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
38. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
[TBL] [Abstract][Full Text] [Related]
39. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.
Abrahami D; Tesfaye H; Yin H; Vine S; Hicks B; Yu OHY; Campeau L; Platt RW; Schneeweiss S; Patorno E; Azoulay L
Diabetes Care; 2022 Dec; 45(12):2907-2917. PubMed ID: 36170656
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]